Valproate–Induced Hepatic Steatogenesis in Rats
Open Access
- 1 November 1982
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 2 (6) , 870-873
- https://doi.org/10.1002/hep.1840020622
Abstract
The administration of high–dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague–Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low–dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed–function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental model may permit exploration of factors that enhance or inhibit VPA–induced hepatic injury.This publication has 18 references indexed in Scilit:
- FATAL HEPATIC FAILURE AND SODIUM VALPROATEThe Lancet, 1980
- FATAL HEPATOTOXICITY IN CHILD ON PHENOBARBITONE AND SODIUM VALPROATEThe Lancet, 1980
- Valproic AcidNew England Journal of Medicine, 1980
- Hepatic Failure from Valproic AcidNew England Journal of Medicine, 1979
- Reye-like syndrome associated with valproic acid therapyThe Journal of Pediatrics, 1979
- Acute Hepatic Failure Associated with the Use of Sodium ValproateNew England Journal of Medicine, 1979
- Metabolism of Valproate Sodium in Rabbit, Rat, Dog, and ManEpilepsia, 1977
- Jamaican Vomiting SicknessNew England Journal of Medicine, 1976
- The Hepatic Lesion in Reye’s SyndromeGastroenterology, 1975
- Production of the Features of Reye's Syndrome in Rats with 4-Pentenoic AcidPediatric Research, 1975